|Mr. Frederic Cren||Co-Founder, CEO & Chairman||572.89k||N/A||1966|
|Dr. Pierre Broqua Ph.D.||Co-Founder, Chief Scientific Officer, Deputy CEO & Director||390.22k||N/A||1962|
|Mr. Jean Volatier||Chief Financial Officer||N/A||N/A||1965|
|Mr. Eric Duranson L.L.M.||Gen. Counsel||N/A||N/A||1974|
|Ms. Nathalie Harroy||Head of HR||N/A||N/A||1967|
|Dr. Irena Konstantinova||Head of Biology & Pharmacology||N/A||N/A||N/A|
|Dr. Michael Cooreman||Chief Medical Officer||N/A||N/A||1958|
|Mr. Jean-Paul Dutertre M.D.||Head of Pharmacovigilance||N/A||N/A||N/A|
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Inventiva S.A.’s ISS governance QualityScore as of 1 January 2023 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 9; Compensation: 5.